

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai Haohai Biological Technology Co., Ltd.\***

**上海昊海生物科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6826)**

### **POSITIVE PROFIT ALERT**

This announcement is published by Shanghai Haohai Biological Technology Co., Ltd.\* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to the Inside Information Provisions under of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The board of directors of the Company (the “**Board**”) hereby informs the shareholders and potential investors of the Company that, based on the information currently available to the Group and its preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2023 (the “**Reporting Period**”), the Group is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB400,000,000 to RMB430,000,000 during the Reporting Period, representing an increase of approximately RMB219,530,300 to RMB249,530,300, or approximately 121.64% to 138.27%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company of RMB180,469,733.31). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB367,000,000 to RMB397,000,000, representing an increase of approximately RMB208,250,400 to RMB238,250,400, or approximately 131.18% to 150.08%, as compared to that in 2022 (corresponding period in 2022: audited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss of RMB158,749,648.52).

As far as the Board is aware, the change in performance for the Reporting Period as compared to the corresponding period in 2022 was mainly attributable to the following:

The suspension of the production and operating activities of the Company and its three production subsidiaries located in Shanghai during the period from March to May 2022, and the asset impairment loss provided on the goodwill and intangible assets of Aaren Scientific Inc. (a subsidiary of the Company in the USA) in 2022 had a material adverse impact on the Group's revenues and profits in 2022. During the Reporting Period, with the stable external operating environment, the Group's production, operation and sales recovered and improved steadily, and the sales volume and revenues of various product lines, with HA dermal filler in particular increased significantly compared with the corresponding period of last year.

The Board hereby reminds the shareholders and potential investors of the Company that the information set out in this announcement is based on an assessment with reference to the information currently available to the Group and has not been reviewed by the audit committee of the Company and the independent auditors. The Group is still finalizing the audited results for the year ended 31 December 2023 (the “**2023 Annual Results**”), which are subject to adjustments (if necessary). The 2023 Annual Results may differ from the data set out in this announcement. Shareholders and potential investors of the Company are advised to read carefully the details of the Group’s 2023 Annual Results, which is expected to be published in early March 2024.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Shanghai Haohai Biological Technology Co., Ltd.\***  
*Chairman*  
**Hou Yongtai**

Shanghai, the PRC, 29 January 2024

*As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.*

\* *For identification purpose only*